DIAGNOSTIC-ANALYSIS, CLINICAL IMPORTANCE AND MOLECULAR-BASIS OF DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY

被引：66

作者：

GONZALEZ, FJ

FERNANDEZSALGUERO, P

机构：

[1] Laboratory of Molecular Carcinogenesis, National Institutes of Health, Bethesda, MD 20892, Building 37

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 1995年 / 16卷 / 10期

关键词：

D O I：

10.1016/S0165-6147(00)89065-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：325 / 327

页数：3

共 23 条

[1] DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY LEADING TO THYMINE-URACILURIA - AN INBORN ERROR OF PYRIMIDINE METABOLISM [J].

BERGER, R ;

STOKERDEVRIES, SA ;

WADMAN, SK ;

DURAN, M ;

BEEMER, FA ;

DEBREE, PK ;

WEITSBINNERTS, JJ ;

PENDERS, TJ ;

VANDERWOUDE, JK .

CLINICA CHIMICA ACTA, 1984, 141 (2-3) :227-234

[2] A NEW CASE OF DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY [J].

BROCKSTEDT, M ;

JAKOBS, C ;

SMIT, LME ;

VANGENNIP, AH ;

BERGER, R .

JOURNAL OF INHERITED METABOLIC DISEASE, 1990, 13 (01) :121-124

[3] CLINICAL-PHARMACOLOGY OF 5-FLUOROURACIL [J].

DIASIO, RB ;

HARRIS, BE .

CLINICAL PHARMACOKINETICS, 1989, 16 (04) :215-237

[4] CLINICAL PHARMACOKINETICS-PHARMACODYNAMICS OF ANTICANCER DRUGS [J].

EVANS, WE ;

RELLING, MV .

CLINICAL PHARMACOKINETICS, 1989, 16 (06) :327-336

[5]

FERNANDEZSALGUE.P, 1995, BIOCHEM PHARMACOL, V50, P1015

[6]

HARRIS BE, 1991, CANCER, V68, P499, DOI 10.1002/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO

[7]

2-F

[8]

LU Z, 1994, BIOCHEM PHARMACOL, V46, P945

[9]

LU ZH, 1992, J BIOL CHEM, V267, P17102

[10] SEVERE 5-FLUOROURACIL TOXICITY IN A PATIENT WITH DECREASED DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY [J].

LYSS, AP ;

LILENBAUM, RC ;

HARRIS, BE ;

DIASIO, RB .

CANCER INVESTIGATION, 1993, 11 (02) :239-240

← 1 2 3 →